Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan G Ball

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 3